



Canasa® (mesalamine) – First-time generic

- On December 17, 2018, [Mylan launched](#) an [AB-rated](#) generic version of Allergan's [Canasa \(mesalamine\)](#) rectal suppositories.
 - Mylan has been granted 180-days of exclusivity.
- Canasa is approved for the treatment of mildly to moderately active ulcerative proctitis in adults.
- Mesalamine is also available generically as [delayed-release 800 mg tablets](#), [delayed-release 1.2 gm tablets](#) and an [enema](#), and as brand extended-release capsules ([Apriso®](#), [Pentasa®](#)) and delayed-release capsules ([Delzicol®](#)).
 - The 800 mg delayed-release tablets are indicated for the treatment of moderately active ulcerative colitis in adults.
 - The 1.2 gm delayed-release tablets are indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis.
 - The enema is indicated for the treatment of active mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis.
 - Apriso is indicated for the maintenance of remission of ulcerative colitis in patients 18 years of age and older.
 - Pentasa is indicated for the induction of remission and for the treatment of patients with mildly to moderately active ulcerative colitis.
 - Delzicol is indicated for the treatment of mildly to moderately active ulcerative colitis in patients 5 years of age and older and for the maintenance of remission of ulcerative colitis in adults.
- According to IQVIA™, U.S. sales for Canasa were approximately \$263 million for the 12 months ending October 31, 2018.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.